Can IASO Bio and Instituto Butantan make CAR-T therapy affordable for Brazil’s public health system?

IASO Bio and Instituto Butantan are betting on local CAR-T development in Brazil. Find out what this could change for access, cost, and cancer care.

IASO Bio and Instituto Butantan are betting on local CAR-T development in Brazil. Find out what this could change for access, cost, and cancer care.